Avocet Bio is developing a novel therapeutic platform technology that specifically detects diseasecausing RNA and deactivates it precisely and rapidly in cells using an enzymatic system (CRISPR/Cas13) without altering the genome. Originally developed during the pandemic as an antiviral therapy against RNA viruses such as SARSCoV-2 (which functions independently of mutations and can also be adapted to new (pandemic) viruses within a very short time), Avocet Bio is currently developing a therapy against the influenza A virus and is also expanding their focus to include other nonviral diseases.